Loading...
OTCM
PROCF
Market cap141mUSD
Jul 02, Last price  
1.40USD
Name

Procaps Group SA

Chart & Performance

D1W1MN
OTCM:PROCF chart
P/E
3.33
P/S
0.35
EPS
0.42
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
410m
+0.04%
324,792,000331,467,000409,742,000409,920,000
Net income
43m
P
-17,013,000-10,447,000-100,863,00042,540,000
CFO
14m
-62.19%
68,286,00070,920,00037,303,00014,106,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
IPO date
Dec 09, 2019
Employees
5,500
Domiciled in
LU
Incorporated in
LU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT